Juno Therapeutics Competitors and Similar CompaniesClear all
Immatics's competitors and similar companies include Kite Pharma and Adaptive Biotechnologies.
 Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. |  Adaptive Biotechnologies Adaptive Biotechnologies (formerly known as Adaptive TCR) is a company that develops diagnostics and therapeutic tools based on the immune response to disease. | ||
Founding Date | Founding Date N/A | Founding Date 2009 | Founding Date 2009 |
Type | Type Public | Type Subsidiary | Type Public |
Tags | |||
Locations | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Santa Monica, US HQ Hoofddorp, NL London, GB El Segundo, US Emeryville, US Frederick, US Oceanside, US see more | Locations Seattle, US HQ New York, US South San Francisco, US |
Employees | Employees 29723% increase | Employees 3,9671% decrease | Employees 70910% decrease |
Valuation ($) | Valuation ($) 1.1 b | Valuation ($) N/A | Valuation ($) 694.6 m |
Financial | |||
Revenue (est.) | Revenue (est.) €48.3m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $277m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $71.4m (FY, 2025) |
Gross profit | Gross profit €53m (FY, 2025) | Gross profit N/A | Gross profit $205.6m (FY, 2025) |
Net income | Net income (€196.4m) (FY, 2025) | Net income N/A | Net income ($59.5m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 267.3m | Total funding raised $ 85.3m | Total funding raised $ 525m |
For sources of this data, please see the company profile
View Company Profiles
Kite Pharma
HQ
Santa Monica, US
Kite Pharma is a company developing cancer immunotherapy products based on cell therapy.
View companyAdaptive Biotechnologies
HQ
Seattle, US
Employees
709↓ 10% decrease
Adaptive Biotechnologies (formerly known as Adaptive TCR) is a company that develops diagnostics and therapeutic tools based on the immune response to disease.
View company